Landais I , Hiddingh S , McCarroll M , Yang C , Sun A , Turker MS , Snyder JP , Hoatlin ME .

CA101690-03 NCI NIH HHS , NIH CA112775 NCI NIH HHS

                Fanconi anemia
                bone marrow disease

	Figure 1. Curcumin analogs efficiently inhibit xFANCD2 monoubiquitylation in Xenopus extracts. A) Inhibition of xFANCD2-Ub and xMRE11 phosphorylation by curcumin anlogs. IC50 values were determined using immunoblots of plasmid-activated extracts treated with a range of concentrations for each compound (0, 10, 25, 60, 150, 400, 1000, 3000 μM). A representative experiment is shown (out of 3 repeats). B) Structure of curcumin and monoketone analogs. C) Curcumin analogs do not affect RPA32 and H2AX phosphorylation. Activated extracts were treated with 1 mM each compound and phosphorylation of RPA32 and H2AX monitored by immunoblot.
	Figure 2. Proteasome inhibition activity of EF24 and related curcumin analogs in Xenopus extracts. A) Inhibition of caspase- and chymotrypsin-like proteasome activities and xFANCD2-Ub by MG132, curcumin and curcumin analogs. Proteasome activities and xFANCD2-Ub were monitored using fluorogenic probes and immunoblotting, respectively. IC50 values were determined for each compound using a range of concentrations and represented in histogram graphs. For MG132, numbers above caspase-like and chymotrypsin-like histograms indicate the actual IC50 values. A representative experiment is shown (out of 3 repeats). B) Inhibition of proteasome activities by EF31 and AS153-4 compared to curcumin.
	Figure 3. EF24 does not inhibit xFANCD2-Ub through modulation of a phosphorylation event, but IKK inhibition might play a role. A) EF24 inhibits the IKK kinase in Xenopus extracts. Extracts treated as indicated were analyzed by immunoblot using xFANCD2, IκB-α and tubulin-α antibodies. IκB-α protein level was used as readout for monitoring IKK inhibition. B) The specific IKK inhibitor compound BMS-345541 (IKK inhibitor III, Calbiochem) inhibits xFANCD2-Ub in extracts. Experiment was performed as in (A). The structure of BMS-345541 is shown. The star denotes a non-specific band used as loading control. C) EF24-dependent inhibition of xFANCD2-Ub is not affected by co-treatment with tautomycin (phosphatase inhibitor), caffeine (kinase inhibitor) and SAP (shrimp alkaline phosphatase). Extracts treated as indicated were analyzed by immunoblot using xFANCD2 and xMRE11 antibodies. xMRE11 phosphorylation status was used to monitor the efficiency of tautomycin, caffeine and SAP treatments.
	Figure 4. EF24 inhibits hFANCD2-Ub and foci formation in HeLa cells and is more active than curcumin. A) Hydroxyurea-induced FANCD2-Ub in HeLa cells is inhibited by EF24 at lower concentrations than curcumin. hFANCD2-Ub was monitored by immunoblot and densitometry analysis to determine IC50. B) Hydroxyurea-induced hFANCD2 foci formation is inhibited by EF24. hFANCD2 foci were detected by immunofluorescence and the percentage of cells with more than 5 foci was determined for each treatment. Histograms represent the average of 3 experiments. Error bars represent standard deviation.
	Figure 5. EF24 sensitizes the HSC 72OT+A cell line to MMC but not its FA-deficient counterpart, HSC 72OT. A) Effect of the combination of MMC and EF24 treatment on the viability of HSC 72OT and HSC 72OT+A cells. HSC 72OT (patient-derived FANCA-deficient cell line) and HSC 72OT+A (FANCA-complemented isogenic cell line) were treated with various concentrations of MMC only (solid lines) or MMC + 100 nM EF24 (dashed lines). Cell viability was measured after 3 days by MTS assay. B) Similar experiment was performed using EF24 only.
	Figure 6. EF24 but not curcumin or DRB is more toxic to ATM-deficient mouse kidney cells than wild-type cells. A) 309ATM KO and 334ATM WT cells were treated with various concentrations of EF24. Cell viability was measured after 3 days by MTS assay. Each point represents the mean of 3 repeats. Error bars represent standard deviation. B) Similar experiment was performed using curcumin. C) Similar experiment was performed using DRB, a caseine kinase II inhibitor that does not inhibit the FA pathway in Xenopus extracts.
	Figure 7. Monoketone analogs of curcumin form a new class of FA pathway inhibitors. A) Identification of 4H-TTD in an independent screen for FA pathway inhibitors. Each compound of row E of the NCI Challenge Set library plate was tested at 0.5 mM in Xenopus extracts for inhibition of xFANCD2-ub and xMRE11-P. Arrow indicates the active compound. The chemical structure of 4H-TTD is shown. B) Comparison of xFANCD2-Ub inhibition activity of 4H-TTD, EF24 and curcumin in Xenopus extracts. xFANCD2-Ub IC50 were determined as in Fig. 1A. C) 4H-TTD inhibits the FA pathway in HeLa cells. IC50 was determined as in Fig. 4A. D) 4H-TTD is more toxic to 309ATM KO than 334ATM WT cells.
	Figure 8. Summary of the mechanistic findings presented in this paper. The ATM and FA pathways (white boxes/arrows) are two DNA damage response pathways that display synthetic lethal relationship. Inhibition of the FA pathway may therefore be used as a targeted therapy to selectively kill ATM-deficient tumors. Several enzymatic complexes have been proposed to modulate the FA pathway (light grey boxes). Monitoring the effect of the compounds used in this study (dark grey boxes) toward those enzymatic activities suggests that (i) in contrast with cell-based assays, the proteasome is not required for FA pathway activation in Xenopus extracts, (ii) in contrast with curcumin, EF24 is a weak proteasome inhibitor, (iii) EF24 does not inhibit the FA pathway through disruption of the core complex, and (iv) curcumin, EF24 and BMS-345541 might inhibit the FA pathway through inhibition of IKK.

Adams, Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. 2004, Pubmed

Adams, Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. 2004, Pubmed
Adams, EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. 2005, Pubmed
Aggarwal, Curcumin: the Indian solid gold. 2007, Pubmed
Ak, Antioxidant and radical scavenging properties of curcumin. 2008, Pubmed
Aleo, Identification of new compounds that trigger apoptosome-independent caspase activation and apoptosis. 2006, Pubmed
Ashworth, A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. 2008, Pubmed
Austen, Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. 2007, Pubmed
Ben-Yehoyada, Checkpoint signaling from a single DNA interstrand crosslink. 2009, Pubmed , Xenbase
Burke, BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. 2003, Pubmed
Chirnomas, Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. 2006, Pubmed
Costanzo, Mre11 protein complex prevents double-strand break accumulation during chromosomal DNA replication. 2001, Pubmed , Xenbase
Czornak, Mystery of DNA repair: the role of the MRN complex and ATM kinase in DNA damage repair. 2008, Pubmed
de Winter, The genetic and molecular basis of Fanconi anemia. 2009, Pubmed
Di Virgilio, PIKK-dependent phosphorylation of Mre11 induces MRN complex inactivation by disassembly from chromatin. 2009, Pubmed , Xenbase
Duckworth-Rysiecki, Identification of two complementation groups in Fanconi anemia. 1985, Pubmed
Dupré, A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. 2008, Pubmed , Xenbase
Fang, Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma. 2003, Pubmed
Fong, Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. 2009, Pubmed
Gage, Spontaneously immortalized cell lines obtained from adult Atm null mice retain sensitivity to ionizing radiation and exhibit a mutational pattern suggestive of oxidative stress. 2001, Pubmed
Gurtan, The WD40 repeats of FANCL are required for Fanconi anemia core complex assembly. 2006, Pubmed
Ho, Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. 2006, Pubmed
Ishiai, FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway. 2008, Pubmed
Jacquemont, Proteasome function is required for DNA damage response and fanconi anemia pathway activation. 2007, Pubmed
Jana, Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. 2004, Pubmed
Kalb, Fanconi anemia: causes and consequences of genetic instability. 2006, Pubmed
Kasinski, Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. 2008, Pubmed
Keiser, Relating protein pharmacology by ligand chemistry. 2007, Pubmed
Kennedy, Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. 2007, Pubmed
Landais, A novel cell-free screen identifies a potent inhibitor of the Fanconi anemia pathway. 2009, Pubmed , Xenbase
Lavin, Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. 2008, Pubmed
Liu, Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. 2000, Pubmed
Luo, A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. 2009, Pubmed
Lupardus, A requirement for replication in activation of the ATR-dependent DNA damage checkpoint. 2002, Pubmed , Xenbase
Otsuki, Fanconi anemia protein complex is a novel target of the IKK signalsome. 2002, Pubmed
Patro, Protective activities of some phenolic 1,3-diketones against lipid peroxidation: possible involvement of the 1,3-diketone moiety. 2002, Pubmed
Rahman, Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players. 2007, Pubmed
Rai, DNA damage response: the players, the network and the role in tumor suppression. 2007, Pubmed
Scholl, Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. 2009, Pubmed
Shoji, Targeting tissue factor-expressing tumor angiogenesis and tumors with EF24 conjugated to factor VIIa. 2008, Pubmed
Sobeck, Fanconi anemia proteins are required to prevent accumulation of replication-associated DNA double-strand breaks. 2006, Pubmed , Xenbase
Sobeck, DNA structure-induced recruitment and activation of the Fanconi anemia pathway protein FANCD2. 2007, Pubmed , Xenbase
Sobeck, The Fanconi anemia protein FANCM is controlled by FANCD2 and the ATR/ATM pathways. 2009, Pubmed , Xenbase
Sun, Synthesis of EF24-tripeptide chloromethyl ketone: a novel curcumin-related anticancer drug delivery system. 2006, Pubmed
Taniguchi, S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. 2002, Pubmed
Thomas, EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. 2008, Pubmed
Tuma, PARP inhibitors: will the new class of drugs match the hype? 2009, Pubmed
Wang, PARP is important for genomic stability but dispensable in apoptosis. 1997, Pubmed
Wang, Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. 2007, Pubmed
Wang, Fanconi anemia proteins stabilize replication forks. 2008, Pubmed , Xenbase
Yang, Finding multiple target optimal intervention in disease-related molecular network. 2008, Pubmed